COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlightsGlobeNewsWire • 02/24/22
COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022GlobeNewsWire • 02/17/22
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depressionGlobeNewsWire • 01/19/22
COMP360 psilocybin study of 89 healthy participants published in Journal of PsychopharmacologyGlobeNewsWire • 01/04/22
Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study ConfirmsBenzinga • 12/13/21
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression studyGlobeNewsWire • 12/13/21
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression ReductionBenzinga • 12/01/21
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depressionGlobeNewsWire • 12/01/21
COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferencesGlobeNewsWire • 11/30/21
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass PathwaysBenzinga • 11/29/21
Why We're Excited About Compass Pathways' Clinical Trial Treating PTSD With PsilocybinBenzinga • 11/22/21
Psychedelic companies say Compass study result validates industry's hope to find alternative treatments for mental healthProactive Investors • 11/18/21